Seeking Alpha

KarinCA's  Instablog

KarinCA
Send Message
I'm an independent trader/investor whose primary interests are in the stem cell and biotech arena. My secondary interest is in oil/energy speculation. I do venture elsewhere at times. OTHER PLACES TO FOLLOW ME: https://twitter.com/KarinCAtrades https://www.facebook.com/karinca.trades... More
  • ISCO Has Promising Therapy For Parkinson's Disease 1 comment
    May 11, 2013 7:26 PM | about stocks: ISCO

    Here are a couple of links that will be of great interest to those concerned with Parkinson's Disease.

    Dr. Ruslan Semechkin, VP of Research and Development will be presenting data at the upcoming Annual Meeting of American Society of Gene and Cell Therapy, May 15-18, 2013

    Quote:

    "CARLSBAD, CA -- (Marketwired) -- 05/01/13 -- International Stem Cell Corporation (OTCQB: ISCO) (internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies announced that Dr. Ruslan Semechkin, VP of Research and Development, will present additional data from the primate study of the use of neuronal cells for the treatment of Parkinson's disease at the 16th Annual Meeting of American Society of Gene and Cell Therapy, May 15-18, 2013 at the Salt Palace Convention Center in Salt Lake City, UT. "

    The results, including more detailed analysis of the safety and functional activity of the cells, will be presented orally at the following session:

    Session: Stem Cell Engineering and Therapy
    Date: Thursday, May 16, 2013
    Time: 2:00 PM
    Room: Ballroom D
    Title: Cell Replacement Therapy for Parkinson's Disease with Neuronal Cells Derived from Human Parthenogenetic Stem Cells

    In addition ISCO will present two posters detailing progress in our pre-clinical metabolic liver disease program and recent achievements with our "safe" iPS cells, induced pluripotent stem cells that do not rely on viral vectors for the genetic reprogramming. The posters will be presented on Thursday, May 16, 2013 between 4:00 pm and 6:00 pm in Exhibit Hall C/D.

    ISCO's breakthrough method of deriving neuronal cells for the treatment of Parkinson's disease was published in Scientific Reports, a primary research publication from the publishers of Nature. Click here for published report.

    Quote:

    "CARLSBAD, CA -- (Marketwire) -- 03/15/13 -- International Stem Cell Corporation (OTCQB: ISCO) (internationalstemcell.com), a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells, announced today the publication of its breakthrough method of deriving neuronal cells for the treatment of Parkinson's disease in Scientific Reports, a primary research publication from the publishers of Nature.

    Parkinson's disease (PD) is a common neurodegenerative disorder caused by a progressive loss of dopamine-producing neurons resulting in gradual dysfunction of the motor system. Pharmacological treatments are useful in the relatively early stage of the disease, but the continuous use of pro-dopaminergic medication eventually becomes ineffective and can worsen some of the motor symptoms. ISCO is developing a treatment for PD based on replacing the lost neurons with new neuronal cells derived from human parthenogenetic stem cells (hpSC). To this end ISCO has developed a sophisticated and efficient manufacturing process for neuronal cells which has now been published in the peer-reviewed journal Scientific Reports.

    The paper describes the technology, developed by ISCO's R&D team, for producing highly pure populations of GMP-grade neuronal cells suitable for pre-clinical studies and clinical trials. The neuronal cells created using this approach are further characterized using a number of analytical methods and shown to function in a similar manner to adult cells. Moreover, neuronal cells produced using this new method, express greater levels of dopamine, the neurotransmitter central to PD, than previously reported approaches. Furthermore, these hpSC-derived neuronal cells are cryopreservable and can be stored frozen, and provides a practical route to creating neurons of sufficient quality to be used to treat Parkinson's disease patients.

    "It is important that our research is reviewed and validated by the scientific community and being able to publish in a Nature-branded, journal provides confirmation of the quality of ISCO's scientific research," commented Dr. Andrey Semechkin, CEO and Co-Chairman."

    Disclosure: I am long OTCQB:ISCO.

Back To KarinCA's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • biomanbaba
    , contributor
    Comments (107) | Send Message
     
    Good Job K. I have always believed that this IND when filed will
    break the $ for ISCO
    11 May 2013, 11:58 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.